Long-term tamoxifen citrate use and potential ocular toxicity*

https://doi.org/10.1016/S0002-9394(99)80190-1Get rights and content

Purpose

To estimate the prevalence of abnormalities in visual function and ocular structures associated with the long-term use of tamoxifen citrate.

Methods

A single-masked, cross-sectional study involving multiple community and institutional ophthalmologic departments was conducted with a volunteer sample of 303 women with breast cancer currently taking part in a randomized clinical trial to determine the efficacy of tamoxifen (20 mg/day) in preventing recurrences. Participants included women who had never been on drug (n = 85); women who had taken tamoxifen for an average of 4.8 years, then been off the drug for an average of 2.7 years (n = 140); and women who had been on tamoxifen continuously for an average of 7.8 years (n = 78). Women were evaluated by questionnaire, psychophysical testing, and clinical examination to determine any abnormalities in visual function and the comparative prevalences of corneal, lens, retinal, and optic nerve pathology.

Results

There were no cases of vision-threatening ocular toxicity among the tamoxifen-treated participants. Compared with nontreated participants, the tamoxifen-treated women had no differences in the activities of daily vision, visual acuity measurements, or other tests of visual function except for color screening. Intraretinal crystals (odds ratio [OR] = 3.58, P =.178) and posterior subcapsular opacities (OR = 4.03, P =.034) were more frequent in the tamoxifen-treated group.

Conclusions

Women should have a thorough baseline ophthalmic evaluation within the first year of initiating tamoxifen therapy and receive appropriate follow-up evaluations.

References (30)

  • BirdAC et al.

    An international classification and grading system for age-related maculopathy and age-related macular degeneration

    Surv Ophthalmol

    (1995)
  • HeierJS et al.

    Screening for ocular toxicity in asymptomatic patients treated with tamoxifen

    Am J Ophthalmol

    (1994)
  • RenfroL et al.

    Ocular effects of topical and systemic corticosteroids

    Dermatol Clin

    (1992)
  • NayfieldSG et al.

    Tamoxifen-associated eye disease: a review

    J Clin Oncol

    (1996)
  • FisherB et al.

    A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors

    N Engl J Med

    (1989)
  • FisherB et al.

    Systemic therapy in patients with node-negative breast cancer: a commentary based on two National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trials

    Ann Intern Med

    (1989)
  • FisherB et al.

    Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen-receptor positive tumors

    J Natl Cancer Inst

    (1996)
  • MangioneCM et al.

    Development of the ‘Activities of Daily Vision Scale’: a measure of visual functional status

    Med Care

    (1992)
  • FerrisFL et al.

    New visual acuity charts for clinical research

    Am J Ophthalmol

    (1987)
  • BowmanKJ

    A method for quantitative scoring of the Farnsworth panel D-15

    Acta Ophthalmol (Copenh)

    (1982)
  • SchneckME et al.

    SKILL card: hidden deficits in ‘recovered’ optic neuritis. ARVO abstracts

    Invest Ophthalmol Vis Sci

    (1992)
  • EngerC et al.

    Recognizing glaucomatous field loss with the Humphrey STATPAC

    Arch Ophthalmol

    (1987)
  • KatzJ et al.

    Comparison of analytic algorithms for detecting glaucomatous visual field loss

    Arch Ophthalmol

    (1991)
  • McKeownC et al.

    Tamoxifen retinopathy

    Br J Ophthalmol

    (1981)
  • ChangT et al.

    Low-dose tamoxifen retinopathy

    Can J Ophthalmol

    (1992)
  • Cited by (118)

    • Tamoxifen retinopathy

      2023, Survey of Ophthalmology
    • Retinal toxicities of systemic anticancer drugs

      2022, Survey of Ophthalmology
      Citation Excerpt :

      Color vision and visual fields (VF). Color discrimination appears to be slightly compromised in tamoxifen users.164,384,401 VF assessment with short wavelength automated perimetry (SWAP) revealed that tamoxifen influenced visual responses mediated by short wavelength sensitive cones, in the periphery as well as at fovea.125,127

    • The effect of sex on the mouse lens transcriptome

      2021, Experimental Eye Research
      Citation Excerpt :

      The prevalent hypothesis in the literature suggests that the withdrawal of estrogen at menopause results in cataract due to a “rebound” effect on the lens (Zetterberg and Celojevic, 2015). This postulate is supported by epidemiological studies finding a correlation between hormonal replacement therapy of menopausal women and protection from cataract (Noran et al., 2007; Younan et al., 2002), while treatment of breast cancer patients with the anti-estrogen, tamoxifen, increases cataract risk (Gorin et al., 1998; Nelson et al., 2019). In other tissues, sex confers more differences on cells than can be explained by just differential exposure to sex hormones, including changes in DNA methylation (Hodes et al., 2017) and the expression of numerous autosomal genes (Arnold, 2019), even prior to embryonic sex determination (Lowe et al., 2015).

    View all citing articles on Scopus
    *

    This study was funded by grant U10CA37377 from the National Institutes of Health, National Cancer Institute, Bethesda, Maryland.

    View full text